Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza

NCT01793883 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

639

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

DRUG: 40 mg Laninamivir Octanoate
DRUG: 80 mg Laninamivir Octanoate
DRUG: Placebo

Sponsor

Biota Scientific Management Pty Ltd

Collaborators

[object Object]